M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma

NCT00257465 Phase 1/Phase 2 COMPLETED

The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own cancer cells.

Details

Lead sponsor	AVAX Technologies
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	82
Start date	2005-06
Completion	2008-06

Conditions

• Melanoma

Interventions

• Autologous, DNP-modified vaccine (M-Vax)
• Autologous, DNP-Modified Melanoma Vaccine
• Autologous, DNP-Modified Vaccine
• Autologous, DNP-Modified Vaccine
• Autologous, DNP-Modified Vaccine

Primary outcomes

• Immune response to patients' own melanoma cells — 2 months

Countries

United States